Therefore, non-viral HCC, and especially NASH-induced HCC, may be less responsive to immunotherapy programs based on anti-PDL1 and anti-VEGF [106] treatments. This evidence concerns the gene VEGFA and metabolic dysfunction-associated steatohepatitis.